Do you want to read an article? Please log in or register.
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Cardiovascular Risk and DiseasesMyocardial InfarctionThrombosis and Stroke
Related content
Heart, Artery and Coronary DiseasesHypertension
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial
Eur Heart J.
Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, Lüscher TF, Solomon DH, Husni ME, Graham DY, Davey DA, Wisniewski LM, Menon V, Fayyad R, Beckerman B, Iorga D, Lincoff AM, Nissen SE
doi: 10.1093/eurheartj/ehx508.
Cardiovascular Risk and Diseases
Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen
J Am Coll Cardiol.
Reed GW, Abdallah MS, Shao M, Wolski K, Wisniewski L, Yeomans N, Lüscher TF, Borer JS, Graham DY, Husni ME, Solomon DH, Libby P, Menon V, Lincoff AM, Nissen SE
doi: 10.1016/j.jacc.2018.02.036.
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial
Lancet.
Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL, Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH
doi: 10.1016/S0140-6736(17)
Cardiovascular Risk and Diseases
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen or Naproxen: a Secondary Analysis of the PRECISION Randomized Controlled Clinical Trial
Am J Med.
Solomon DH, Husni ME, Libby PA, Yeomans ND, Lincoff AM, Lüscher TF, Menon V, Brennan DM, Wisniewski LM, Nissen SE, Borer JS
doi: 10.1016/
HypertensionMyocardial InfarctionThrombosis and StrokeTherapy and Intervention
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial
JAMA Intern Med.
Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM
doi: 10.1001/jamainternmed.
Cardiovascular Risk and DiseasesMyocardial InfarctionThrombosis and StrokeTherapy and Intervention
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
N Engl J Med.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L
doi: 10.1056/NEJMoa1710895.
Cardiovascular Risk and Diseases
Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study
Heart.
Nikiphorou E, de Lusignan S, Mallen CD, Khavandi K, Bedarida G, Buckley CD, Galloway J, Raza K
doi: 10.1136/heartjnl-2019-316193.
RECOMMENDED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA Cardiol.
Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP
doi: 10.1001/jamacardio.2020.3151.
Cardiovascular Risk and Diseases
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT
Circulation.
Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula E, Braunwald E; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators
doi: 10.1161/CIRCULATIONAHA.